Glypican-3 is overexpressed in human hepatocellular carcinoma

Cancer Science

Volumn 94, Issue 3, 2003, Pages 259-262

  Sung, Young Kwan ^a   Hwang, Sun Young ^a   Park, Mi Kyung ^a   Farooq, Mohammad ^a   Han, In Sook ^a   Bae, Han Ik ^a   Kim, Jung Chul ^a   Kim, Moonkyu ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GERANYLTRANSFERASE; GLYPICAN; GLYPICAN 3; LONG CHAIN FATTY ACID COENZYME A LIGASE; MOLECULAR MARKER; POLYCLONAL ANTIBODY; SOMATOMEDIN B; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DIAGNOSTIC VALUE; DNA MICROARRAY; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN SECRETION; SCREENING TEST; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0038752042     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01430.x     Document Type: Article

References (26)

1. Filmus J, Shi W, Wong ZM, Wong MJ. Identification of a new membrane-bound heparan sulphate proteoglycan. Biochem J 1995; 311: 561-5.
2. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996; 12: 241-7.
3. Cano-Gauci DF, Song HH, Yang H, McKerlie C, Chou B, Shi W, Pullano R, Piscione TD, Grisaru S, Soon S, Sedlackova L, Tanswell AK, Mak TW, Yeger H, Lockwood GA, Rosenblum ND, Filmus J. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol 1999; 146: 255-64.
4. Paine-Saunders S, Viviano BL, Zupicich J, Skarnes WC, Saunders S. Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol 2000; 225: 179-87.
5. Chiao E, Fisher P, Crisponi L, Deiana M, Dragatsis I, Schlessinger D, Pilia G, Efstratiadis A. Overgrowth of a mouse model of the Simpson-Golabi-Behmel syndrome is independent of IGF signaling. Dev Biol 2002; 243: 185-206.
6. Gonzalez AD, Kaya M, Shi W, Song H, Testa JR, Penn LZ, Filmus J. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 1998; 141: 1407-14.
7. Lin H, Huber R, Schlessinger D, Morin PJ. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999; 59: 807-10.
8. Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J, Testa JR. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 2000; 19: 410-6.
9. Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001; 20: 7408-12.
10. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997; 57: 5179-84.
11. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J, Buchler MW. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001; 48: 558-64.
12. Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer 2000; 89: 418-22.
13. Lisitsyn N, Wigler M. Cloning the differences between two complex genomes. Science 1993; 259: 946-51.
14. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996; 14: 457-60.
15. Park JG, Lee JH, Kang MS, Park KJ, Jeon YM, Lee HJ, Kwon HS, Park HS, Yeo KS, Lee KU, Kim ST, Chung JK, Hwang YJ, Lee HS, Kim CY, Lee YI, Chen TR, Hay RJ, Song SY, Kim WH, Kim CW, Kim YI. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 1995; 62: 276-82.
16. Hubank M, Schatz DG. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 1994; 22: 5640-8.
17. Chung EJ, Sung YK, Farooq M, Kim YH, Tak WY, Hwang YJ, Kim YI, Han HS, Kim JC, Kim MK. Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol Cells 2002; 14: 382-7.
18. Sung YK, Moon C, You JY, Moon C, Pearse D, Pevsner J, Ronnett GV. Plunc, a member of the secretory gland protein family, is up-regulated in nasal respiratory epithelium after olfactory bulbectomy. J Biol Chem 2002; 277: 12762-9.
19. Liu W, Litwack ED, Stanley MJ, Langford JK, Lander AD, Sanderson RD. Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions. J Biol Chem 1998; 273: 22825-32.
20. Cao Y, Dave KB, Doan TP, Prescott SM. Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res 2001; 61: 8429-34.
21. Foo NC, Yen TS. Activation of promoters for cellular lipogenic genes by hepatitis B virus large surface protein. Virology 2000; 269: 420-5.
22. Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D, Czech MP, Ullrich A, Brechot C. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988; 48: 6844-9.
23. Mast AE, Higuchi DA, Huang ZF, Warshawsky I, Schwartz AL, Broze GJ Jr. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J 1997; 327: 577-83.
24. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001; 108: 497-501.
25. Coggin JH Jr. The implications of embryonic gene expression in neoplasia. Crit Rev Oncol Hematol 1986; 5: 37-55.
26. Matsuura H, Hakomori S. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc Natl Acad Sci USA 1985; 82: 6517-21.